• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Nausea And Vomiting - Pipeline Review, H2 2011 - Product Image

Nausea And Vomiting - Pipeline Review, H2 2011

  • ID: 1881651
  • August 2011
  • 160 pages
  • Global Markets Direct

Nausea And Vomiting - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Nausea And Vomiting - Pipeline Review, H2 2011', provides an overview of the Nausea And Vomiting therapeutic pipeline. This report provides information on the therapeutic development for Nausea And Vomiting, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nausea And Vomiting. 'Nausea And Vomiting - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Nausea And Vomiting.
- A review of the Nausea And Vomiting products under development by companies and universities/research READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nausea And Vomiting Overview
Therapeutics Development
An Overview of Pipeline Products for Nausea And Vomiting
Nausea And Vomiting Therapeutics under Development by Companies
Nausea And Vomiting Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Nausea And Vomiting Therapeutics - Products under Development by Companies
Nausea And Vomiting Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Nausea And Vomiting Therapeutics Development
BioDelivery Sciences International, Inc.
GlaxoSmithKline plc
Merck & Co., Inc.
A.P. Pharma, Inc.
Archimedes Pharma Limited
Aphios Corporation
Axcan Pharma Inc.
Eisai Co., Ltd.
Ono Pharmaceutical Co., Ltd.
ProStrakan Group plc
BioAlliance Pharma SA
Teikoku Pharma USA, Inc.
Dharma Therapeutics, Inc.
Simbec Research Ltd
Helsinn Healthcare S.A.
Victory Pharma, Inc.
Ikano Therapeutics, Inc.
Almac Discovery Ltd.
Acacia Pharma Ltd.
Nausea And Vomiting - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Rolapitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EUR 1025 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AB-1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antiemetic - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diphenhydramine hydrochloride + Dexamethasone + Lorazepam + Ondansetron hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aprepitant + Ondansetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Granisetron + Dexamethasone + Prochlorperazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aprepitant + Palonosetron + Dexamethasone for Nausea and Vomiting - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fosaprepitant Dimeglumine + Palonosetron Hydrochloride + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ondansetron Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fosaprepitant for Nausea and Vomiting (Oregon Health and Science University) - Drug Profile
Casopitant + Ondansetron + Dexamethasone - Drug Profile
MK0869 + MK0517 - Drug Profile
Ramosetron + Aprepitant + Dexamethasone - Drug Profile
Gabapentin - Drug Profile
Aprepitant + Palonosetron + Dexamethasone - Drug Profile
Dexamethasone + Granisetron - Drug Profile
Aprepitant - Drug Profile
Proemend - Drug Profile
Dexamethasone - Drug Profile
Nausea And Vomiting Therapeutics – Drug Profile Updates
Nausea And Vomiting Therapeutics - Discontinued Products
Nausea And Vomiting - Featured News
Jun 10, 2011: SNBL Receives Formal Notice From FDA Regarding NDA Submission Of Intranasal Granisetron
Apr 25, 2011: A.P. Pharma Provides Regulatory Update On APF530 NDA
Feb 16, 2011: Acacia Pharma Initiates Phase IIa Clinical Trial With APD421 For Nausea And Vomiting
Feb 16, 2011: Acacia Pharma Initiates Phase IIa Clinical Trial With APD421 For Nausea And Vomiting
Feb 09, 2011: A.P. Pharma Provides Update On APF530 Program
Feb 02, 2011: Helsinn Receives Scientific Advice From EMA Supporting Phase III Trial Program Of Fixed-Dose Combination Of Netupitant And Palonosetron
Jan 12, 2011: Helsinn And Eisai Report FDA Agrees To SPA To Evaluate Fixed-Dose Combination Of Netupitant And Palonosetron
Sep 24, 2010: Ono Files Application In Japan For Intravenous Antiemetic Selective Neurokinin-1 Receptor Antagonist, Fosaprepitant
Sep 06, 2010: Acacia Pharma To Progress Two Projects For Nausea & Vomiting And Xerostomia Into Clinical Development
Jun 02, 2010: Merck Announced Results From Non-Inferiority Trial Of Fosaprepitant Dimeglumine And dexamethasone For Prevention Of Chemotherapy-Induced Nausea and Vomiting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Nausea And Vomiting, H2 2011
Products under Development for Nausea And Vomiting – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
BioDelivery Sciences International, Inc., 2011
GlaxoSmithKline plc, 2011
Merck & Co., Inc., 2011
A.P. Pharma, Inc., 2011
Archimedes Pharma Limited, 2011
Aphios Corporation, 2011
Axcan Pharma Inc., 2011
Eisai Co., Ltd., 2011
Ono Pharmaceutical Co., Ltd., 2011
ProStrakan Group plc, 2011
BioAlliance Pharma SA, 2011
Teikoku Pharma USA, Inc., 2011
Dharma Therapeutics, Inc., 2011
Simbec Research Ltd, 2011
Helsinn Healthcare S.A., 2011
Victory Pharma, Inc., 2011
Ikano Therapeutics, Inc., 2011
Almac Discovery Ltd., 2011
Acacia Pharma Ltd., 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Nausea And Vomiting Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Nausea And Vomiting, H2 2011
Products under Development for Nausea And Vomiting – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos